Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Viva Biotech Holdings (VBIZF)
Shanghai, CN
As an investment holding enterprise, Viva Biotech Holdings provides comprehensive drug discovery services, leveraging a structure-based approach for biotechnology and pharmaceutical clients across the globe. Their offerings encompass discovery biology, including protein expression and purification, structural biology, identification of promising drug candidates (hit discovery), bioassay development, analysis of biomolecular interactions, and pharmacokinetics. They also deliver a range of chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, preparation for purification, and computer-aided drug design (CADD), supported by advanced chemical technology platforms. Furthermore, Viva Biotech excels in antibody drug research and development. These services span from antigen preparation and multi-species discovery to the generation of monoclonal antibodies, functional screening and identification, engineering transformation, characterization, and cell line engineering. They utilize a suite of sophisticated technology platforms for this, including hybridoma, phage, yeast, and mammalian display systems, VHH antibody technology, high-throughput sequencing, computer-aided drug design (CADD), HDX-MS, protein crystal structure determination, and SPR technology. The company additionally supplies crucial research materials such as cell lines, crystal structures, GPCR proteins, various antibodies, and other key proteins. Beyond R&D, Viva Biotech offers contract development and manufacturing (CDMO) for small molecule active pharmaceutical ingredients (APIs) and their intermediates. They are also involved in the trading of APIs, intermediates, and finished formulations, and uniquely provide an "equity for service" model. Additional services include general research support, laboratory space rental, project management, bidding assistance, and the sale of chemical compounds. Established in 2008, the company is headquartered in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -2.67% | -42.55% | -42.55% | -25.07% | +1.74% | -18.48% | +45.17% | -85.39% | -65.08% | -65.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%-15.2% Q4'25: -12.9% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+52.7% ★ Q4'25: +282.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+4.5% Q4'25: +5.1% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+11.2% ★ Q4'25: +8.6% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+3.8% ★ Q4'25: +6.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+9.2% Q4'25: -55.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.38× Q4'25: 1.87× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
323.06M
est: 316.38M (+2.1%)
|
696.96M
est: 752.35M (-7.4%)
|
2.10B
est: 2.28B (-7.7%)
|
2.38B
est: 2.72B (-12.4%)
|
2.16B
est: 2.59B (-16.9%)
|
1.99B
est: 2.97B (-33.0%)
|
1.68B
est: 1.83B (-7.8%)
|
2.20B
2.20B – 2.20B
+20.2% YoY
|
2.53B
2.53B – 2.53B
+15.3% YoY
|
2.86B
2.86B – 2.86B
+12.8% YoY
|
857.77M
857.77M – 857.77M
-70.0% YoY
|
| EBITDA |
88.37M
est: 67.07M (+31.7%)
|
164.35M
est: 159.50M (+3.0%)
|
369.94M
est: 483.20M (-23.4%)
|
436.35M
est: 575.72M (-24.2%)
|
391.01M
est: 550.06M (-28.9%)
|
563.46M
est: 627.87M (-10.3%)
|
393.87M
est: 386.46M (+1.9%)
|
464.46M
464.46M – 464.46M
+20.2% YoY
|
535.61M
535.61M – 535.61M
+15.3% YoY
|
604.32M
604.32M – 604.32M
+12.8% YoY
|
181.50M
181.50M – 181.50M
-70.0% YoY
|
| EBIT |
54.32M
est: 41.21M (+31.8%)
|
112.54M
est: 97.98M (+14.9%)
|
236.90M
est: 296.85M (-20.2%)
|
265.98M
est: 353.68M (-24.8%)
|
192.68M
est: 337.91M (-43.0%)
|
349.60M
est: 356.95M (-2.1%)
|
188.26M
est: 219.70M (-14.3%)
|
264.05M
264.05M – 264.05M
+20.2% YoY
|
304.50M
304.50M – 304.50M
+15.3% YoY
|
343.56M
343.56M – 343.56M
+12.8% YoY
|
103.18M
103.18M – 103.18M
-70.0% YoY
|
| Net Income |
265.87M
est: 190.70M (+39.4%)
|
-386.88M
est: -209.43M (-84.7%)
|
287.55M
est: 472.07M (-39.1%)
|
-528.48M
est: 382.80M (-238.1%)
|
-116.11M
est: 286.35M (-140.5%)
|
167.29M
est: 470.04M (-64.4%)
|
214.09M
est: 233.86M (-8.5%)
|
289.47M
289.47M – 289.47M
+23.8% YoY
|
385.95M
385.95M – 385.95M
+33.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
54.79M
est: 55.24M (-0.8%)
|
123.26M
est: 131.37M (-6.2%)
|
321.70M
est: 397.97M (-19.2%)
|
404.45M
est: 474.17M (-14.7%)
|
409.66M
est: 453.03M (-9.6%)
|
364.12M
est: 537.33M (-32.2%)
|
352.52M
est: 330.73M (+6.6%)
|
397.48M
397.48M – 397.48M
+20.2% YoY
|
458.38M
458.38M – 458.38M
+15.3% YoY
|
517.18M
517.18M – 517.18M
+12.8% YoY
|
155.33M
155.33M – 155.33M
-70.0% YoY
|
| EPS |
0.19
est: 0.09 (+113.4%)
|
-0.25
est: -0.10 (-155.7%)
|
0.15
est: 0.22 (-31.9%)
|
-0.28
est: 0.18 (-256.7%)
|
-0.06
est: 0.13 (-144.7%)
|
0.08
est: 0.20 (-61.0%)
|
0.10
est: 0.10 (+0.0%)
|
0.12
0.12 – 0.12
+23.8% YoY
|
0.16
0.16 – 0.16
+33.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen Cheney Mao | Chairman & Chief Executive Officer | 584.4K | — |
| Delin Ren | Executive Director | 537.1K | — |
| Ying Wu | Executive Vice President & Executive Director | 134.4K | male |
| Jianguo Ma | Senior Vice President & President of Shanghai Langhua Pharmaceutical | — | — |
| Jianhua Cai | Senior Vice President of Via Biotech Shanghai | — | male |
| Rongqiang Liu | Senior Vice President of Via Biotech Shanghai | — | — |
| Susan Chen | Chief Technology Officer | — | — |
| Wei Xiong | Chief Financial Officer | — | male |
| Xianyong Bu | CBO & EVice President of Viva Biotech (Shanghai) | — | male |
| Xueheng Cheng | Chief Technology Officer | — | male |
| Zhixiong Ye | Chief Scientific Officer | — | — |
| Derek Ren | Chief Executive Officer of Viva Biotech (Shanghai) Ltd. | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VBIZF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
